Incidence of Hypercoagulable Events after Image-Guided Percutaneous Cryoablation of Renal Tumors: A Single-Center Experience

Abstract

Purpose To retrospectively identify hypercoagulable events that occurred over time in patients who underwent image guided percutaneous renal cryoablation, and compare the incidence to a cohort of patients who underwent surgical partial nephrectomy (PN) during the same time period. Methods An electronic medical record database was queried for patients who underwent percutaneous image guided renal mass cryoablation or PN between September 2006 and June 2012. Records were examined for thrombotic events during the year following the procedure in each group. Incidence rates, Kaplan-Meier estimates, and patient demographic variables were compared using the stratified log-rank test and the t-test for independent samples. Results One hundred fourteen cryoablation cases were included. The cumulative incidence of thrombotic events after 1-year was 4.39%. The incidence per 100 person-years was 4.84. One hundred five PN cases were included. The cumulative incidence of thrombotic events after 1-year was 1.0%. The incidence per 100 person-years was 1.14. The person-time incidence rate difference for these two groups did not reach statistical significance (p = 0.0894). Conclusion The incidence of thrombotic events in patients who underwent percutaneous renal cryoablation in this study was not significantly different than a comparable cohort who underwent surgical PN during the same time period.

Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results

“…It has been postulated that changes in patients' coagulation profiles after CA due to release of proinflammatory and procoagulative mediators subsequent to cell death can increase such events by creating a hypercoagulable state. Comparing the rates of VTE events between PCA and PN, Hartman and colleagues did not detect a statistically significant difference in the incidence of a thrombotic event per 100 person-years (4.84% vs 1% for PCA and PN, respectively; p = 0.08) [70]; however, given the absolute difference in the rate of thrombotic events between the two groups and the small sample size of the study, a larger study looking at this specific complication is warranted. …”

Transperineal cryotherapy for unresectable muscle invasive bladder cancer: preliminary experience with 7 male patients

“…Cryosurgery, also known as cryoablation, is widely used as primary or salvage treatment for various urological malignances like renal cell carcinoma (RCC) and prostate cancer (PC) in recent years [ 18 – 21 ]. It is reported that cryosurgery offers benefits with fewer complications, shorter hospitalization times, and allows for quicker convalescence in the treatment of RCC and PC [ 22 – 25 ]. Transperineal cryosurgery for prostate cancer has been carried out since 2006 in our hospital.…”